By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Relay Therapeutics, with the key risk being the binary outcome of the Phase 3 trial in 2027 and the potential for safety signals or enrollment delays to erode value rapidly. The company's cash runway is seen as insufficient given the high burn rate and the long timeline to commercialization.
Risk: Binary outcome of the Phase 3 trial in 2027 and potential safety signals or enrollment delays
Opportunity: None identified
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Relay had its initial public offering in 2020.
The company's lead therapy is being tested for the treatment of vascular disorders and cancers.
The company has plenty of cash to develop its therapies.
Relay Therapeutics (NASDAQ: RLAY) is a clinical-stage biotech company focused on cancers and genetic diseases, using a computational platform to identify small-molecule therapies. Relay's stock is up more than 344% over the past year, and it jumped more than 6% in the early afternoon on May 19, the day the company announced promising results for one of its drug therapies.
Relay recently presented phase 2 trial data for zovegalisib in the treatment of vascular anomalies. Zovegalisib works by blocking PIK3CA, a gene that encodes an enzyme involved in cell growth. PIK3CA mutations are often associated with cancer. Vascular anomalies are rare disorders with abnormal development of blood vessels, lymphatic vessels, and surrounding tissues.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The results showed that zovegalisib led to a volumetric response in about 60% of the 20 patients it evaluated. Responses were seen in PROS and lymphatic malformation patients, and across a spectrum of PIK3CA mutations. PROS is an umbrella term for a group of rare genetic disorders caused by mutations in the PIK3CA gene.
Given this new development, some investors may be revisiting their investment views around Relay Therapeutics. Let's look at three reasons to buy Relay Therapeutics and one not to.
Zovegalisib is the healthcare company's lead therapy. In February, the Food and Drug Administration granted the PI3Ka inhibitor a breakthrough therapy designation for patients with PIK3CA-mutant HR+/HER2-advanced breast cancer. The drug has already shown an impressive median progression-free survival of 11.1 months in heavily pretreated, CDK4/6-experienced patients. The new data for vascular anomalies expands its therapeutic possibilities beyond oncology.
According to Relay, there are approximately 140,000 patients with HR+/HER2- breast cancer with a PI3Kα mutation that zovegalisib could help as well as roughly 170,000 patients with vascular anomalies driven by a PI3Kα mutation, both relatively large patient populations.
Unlike many early-stage biotechs that struggle to transition into definitive registration trials, the Cambridge, Mass., company has mapped out a highly structured path to market. Relay has finished a clinical collaboration with Pfizer to supply the CDK4 inhibitor atirmociclib for a triplet combination study, pairing it with Relay's zovegalisib, previously known as RLY-2608, and hormone therapy fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. Relay is on track to initiate a crucial phase 3 frontline trial for the combination study in early 2027, advancing it toward commercial viability.
Relay has three other therapies in its pipeline besides zovegalisib: RLY-8161, which targets NRAS (a gene) solid tumors; a-Gal, designed to treat the rare genetic kidney disorder Fabry Disease; and Lirafugratinib, a cancer therapy it has licensed to Elevar Therapeutics. The drug is a selective inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers.
The biggest killer of clinical-stage biotechs is running out of money before finishing trials. Relay is well capitalized, reporting approximately $642 million in cash and cash equivalents. That's due partly to a successful initial public offering in 2020 that raised $400 million.
Management projects its capital will fund operations well into 2029. This timeline provides the company with a massive buffer to read out late-stage clinical data without being desperately dependent on the immediate whims of a volatile capital market.
Despite its robust cash pile, Relay is a pre-revenue, clinical-stage biotech subject to extreme binary risk. Wall Street analysts project a 36% annualized revenue decline for the full year of 2026 (falling to an estimated consensus of $9.84 million), with per-share losses increasing by 5% to around $1.64.
Because the vast majority of the company's valuation is tied directly to the clinical and regulatory success of zovegalisib, any unexpected safety issue, adverse event trend in broader testing, or failure to meet primary endpoints in the upcoming phase 3 trial would result in a massive, rapid destruction of shareholder value. You're investing in a scientific hypothesis that has not yet crossed the finish line in the commercial world.
Before you buy stock in Relay Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Relay Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $481,589! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,345,714!
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 22, 2026. *
James Halley has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"RLAY remains a high-burn binary bet where phase 3 initiation in 2027 leaves ample time for value destruction despite the cash buffer."
RLAY's phase 2 data in 20 vascular anomaly patients shows 60% volumetric response, expanding zovegalisib beyond breast cancer, yet the article underplays that the pivotal phase 3 triplet trial with Pfizer's atirmociclib only starts in early 2027. With $642M cash funding into 2029 and zero revenue, any delay or safety signal in PI3K inhibition erodes value rapidly. Analysts already forecast 36% revenue drop to $9.84M in 2026 alongside widening losses, highlighting binary clinical risk in a space with established competitors.
Positive phase 2 momentum plus breakthrough designation could trigger an early partnership or acquisition before phase 3 data, de-risking the story faster than the long runway suggests.
"A 60% response rate in 20 uncontrolled vascular patients does not de-risk a company whose entire valuation hinges on a Phase 3 trial 18 months away, especially after a 344% run-up."
Relay's 60% volumetric response in 20 vascular anomaly patients is encouraging but statistically fragile—small N, no comparator arm, and no progression-free survival data yet. The real test is the Phase 3 breast cancer trial launching early 2027; that's 18+ months away with binary risk. The $642M cash runway to 2029 is solid, but the article omits a critical detail: burn rate. At current pre-revenue stage, $642M could evaporate faster than projected if Phase 3 enrollment lags or safety signals emerge. The 344% one-year rally has already priced in significant upside; downside from here is steeper than upside.
If zovegalisib's Phase 3 breast cancer trial succeeds and vascular anomalies become a secondary revenue stream, RLAY could have two distinct markets with 310K+ addressable patients—justifying a higher multiple than current biotech comps and supporting the rally.
"The current valuation overestimates the probability of clinical success while failing to account for the substantial dilution risk inherent in funding a multi-year, pre-revenue pipeline through 2029."
Relay Therapeutics is currently a classic 'show-me' story. While the 60% volumetric response in vascular anomalies is encouraging, the market is pricing in a high probability of success for zovegalisib that ignores the brutal reality of Phase 3 execution. The company’s cash runway into 2029 is a notable defensive moat, but it also signals that management expects a long, expensive slog before commercialization. With a 36% projected revenue decline in 2026, investors are essentially paying a premium for a binary outcome in 2027. The stock’s 344% run-up suggests significant 'hype-premium' is baked in, leaving little margin for error regarding safety signals or regulatory hurdles.
The 'hype' may actually be a rational pricing of Relay's proprietary computational platform, which could theoretically accelerate drug discovery cycles far beyond their current pipeline, creating value that isn't captured in traditional clinical-stage valuation models.
"Relay's upside hinges on definitive, safe efficacy from Phase 3 for zovegalisib; without that, the stock faces steep downside despite a robust cash position."
Relay Therapeutics is rallying on zovegalisib's potential, highlighted by Phase 2 vascular-anomaly data (about 60% volumetric response in 20 patients) and a Breakthrough Therapy designation with an 11.1-month median PFS in HR+/HER2- advanced breast cancer. A Pfizer collaboration aims to push a triple combo into a Phase 3 frontline trial by 2027, and a cash cushion (~$642M) funds ops into 2029. Yet the core risk is binary: Phase 2 signals in small, heterogeneous cohorts rarely guarantee Phase 3 success, especially for PI3Kα inhibitors with known tolerability issues. The entire thesis hinges on zovegalisib delivering definitive, safe efficacy to support a commercial path.
Phase 3 could disappoint despite Phase 2 signals; small sample sizes and safety/tolerability hurdles for PI3Kα inhibitors could derail the thesis, regardless of the Pfizer collaboration or cash runway.
"Platform acceleration cannot fix statistical fragility of the existing small-N data ahead of 2027 readout."
Gemini's platform thesis ignores the execution risk Claude highlighted: even if Relay's modeling speeds discovery, the 20-patient vascular anomaly dataset remains too thin to de-risk a 2027 Phase 3 in breast cancer. That leaves the $642M runway exposed to the exact enrollment delays and safety signals already baked into the 36% 2026 revenue drop forecast.
"The $642M runway is illusory if burn accelerates during Phase 3 enrollment; Relay likely needs external capital or a deal by 2027, eliminating the 'defensive moat' narrative."
Claude and Gemini both assume $642M funds through 2029, but neither questions the burn-rate math. At typical biotech pre-revenue burn ($30-50M annually), that runway compresses to 2027-28—precisely when Phase 3 readout hits. If enrollment stalls or safety signals emerge mid-trial, Relay faces dilutive financing or partnership capitulation before data. The cash cushion isn't a moat; it's a countdown timer masquerading as runway.
"Relay's actual cash burn rate significantly shortens the runway, making massive dilution inevitable well before the 2027 Phase 3 readout."
Claude, your $30-50M annual burn estimate is wildly optimistic for a company entering Phase 3. Relay’s R&D expenses actually topped $300M in 2023. At that velocity, the '2029 runway' is a fantasy; they will need a massive capital raise by late 2026. This isn't just a clinical risk; it is a structural liquidity trap. Investors ignoring this burn rate are miscalculating the impending dilution required to bridge the gap to any potential commercialization.
"Liquidity risk dominates; even with a 2029 runway, financing dynamics could derail the thesis far sooner if data delays or safety signals emerge."
Claude, your burn-rate concern is legitimate but incomplete—the real liquidity risk is timing. If Phase 3 enrollment stalls or safety signals appear, Relay faces rapid dilution or forced financing well before 2029. Gemini’s ~$300M burn in 2023 implies a fragile runway; a 2027 readout may be moot if financing collapses earlier. The core risk is liquidity management under a binary outcome.
The panel consensus is bearish on Relay Therapeutics, with the key risk being the binary outcome of the Phase 3 trial in 2027 and the potential for safety signals or enrollment delays to erode value rapidly. The company's cash runway is seen as insufficient given the high burn rate and the long timeline to commercialization.
None identified
Binary outcome of the Phase 3 trial in 2027 and potential safety signals or enrollment delays